ArticlePloS one2026
Implanted injection port for routine drug delivery to the middle ear in mice.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small molecule drugs designed to rescue disorder-specific mutant proteins causative of progressive sensorineural hearing loss need to be delivered regularly. An example is clarin-1 N48K in Usher syndrome type IIIA (USH3A). In these cases, local delivery has significant advantages over systemic delivery. Genetic predisposition to sensorineural hearing loss may mean the invasive (surgical) approach to access the cochlea is detrimental to hearing preservation. Alternatively, delivering drugs near the round and oval window from the middle ear or tympanic cavity via a tympanostomy tube may be a viable option to treat genetic hearing loss. To test the hypothesis in a mouse model, we first must develop a way to routinely deliver the drugs to the tympanic cavity space in mice that is minimally detrimental to hearing and translatable to humans. Limitations of size and other practical considerations preclude implantation of a tympanostomy tube in mice. The goal of this pilot study was to determine feasibility and assess the impact of implanting an injection port in mice. This approach would serve as a surrogate for drug delivery through tympanostomy tubes in humans. We repurposed the Vascular Access Button (Instech Labs, PA) to access the tympanic cavity in mice that mimics hearing loss in USH3A and its wild-type counterpart. The right ear served as the non-surgical control for all mice. At 2- and 4-weeks post-operation, we monitored behavior, physical attributes, balance, and hearing. The implant was generally well-tolerated in mice. Saline injections through the port were tested for two weeks post-operation without issue, and hearing was not significantly affected. Here, we present a fully implantable method in mice for routine drug delivery to the middle ear, with minimal damage or implant-induced hearing loss. This approach could be used to investigate drug therapies in preclinical models of sensorineural hearing loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.